Ramucirumab + Placebo + Erlotinib + Gefitinib + Osimertinib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non-Small Cell Lung Cancer
Conditions
Metastatic Non-Small Cell Lung Cancer
Trial Timeline
May 6, 2015 → Dec 1, 2026
NCT ID
NCT02411448About Ramucirumab + Placebo + Erlotinib + Gefitinib + Osimertinib
Ramucirumab + Placebo + Erlotinib + Gefitinib + Osimertinib is a phase 3 stage product being developed by Eli Lilly for Metastatic Non-Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02411448. Target conditions include Metastatic Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02411448 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Non-Small Cell Lung Cancer